• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Heart failure and stroke risks in users of liothyronine with or without levothyroxine compared to levothyroxine alone: A propensity score matched analysis
CONCLUSIONS: The use of LT3 was associated with increased incidence of heart failure and stroke in patients with a longer duration of LT3 use and history of thyroid cancer. Therefore, clinicians should consider the risk of heart failure and stroke in thyroid cancer patients with long-term use of LT3. These findings require confirmation in other populations.PMID:35570696 | DOI:10.1089/thy.2021.0634
Source: Thyroid : official journal of the American Thyroid Association - May 16, 2022 Category: Endocrinology Authors: Wook Yi Bo Hyun Kim Mijin Kim Jinmi Kim Myungsoo Im Soree Ryang Eun Heui Kim Yun Kyung Jeon Sang Soo Kim In Joo Kim Source Type: research

Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
Publication date: Available online 6 December 2017 Source:The Lancet Diabetes & Endocrinology Author(s): M Angelyn Bethel, Rishi A Patel, Peter Merrill, Yuliya Lokhnygina, John B Buse, Robert J Mentz, Neha J Pagidipati, Juliana C Chan, Stephanie M Gustavson, Nayyar Iqbal, Aldo P Maggioni, Peter Öhman, Neil R Poulter, Ambady Ramachandran, Bernard Zinman, Adrian F Hernandez, Rury R Holman Background Glucagon-like peptide-1 (GLP-1) receptor agonists are effective glucose-lowering drugs. Findings from cardiovascular outcome trials showed cardiovascular safety of GLP-1 receptor agonists, but results for cardiovascular...
Source: The Lancet Diabetes and Endocrinology - December 6, 2017 Category: Endocrinology Source Type: research

Risk of Adverse Cardiovascular Outcomes in Differentiated Thyroid Cancer Survivors: A Systematic Review and Meta-analysis
CONCLUSION: There is limited evidence suggesting that DTC survivors may be at increased risk of CV death and atrial fibrillation (after adjustment for confounders). We did not observe a significantly increased risk of ischemic heart disease, stroke, or heart failure. Most analyses were subject to significant heterogeneity and further research, with careful attention to CV risk factors, is needed to clarify CV risk in DTC survivors.PMID:36074932 | DOI:10.1089/thy.2022.0209
Source: Thyroid : official journal of the American Thyroid Association - September 8, 2022 Category: Endocrinology Authors: Judy Qiang Raad Alwithenani Elizabeth Uleryk Shereen Ezzat Lorraine L Lipscombe Anna M Sawka Source Type: research

Acromegaly at diagnosis in 3173 patients from the Liege Acromegaly Survey (LAS) Database
In conclusion, this study of >3100 patients is the largest international acromegaly database and shows clinically relevant trends in the characteristics of acromegaly at diagnosis.
Source: Endocrine-Related Cancer - August 22, 2017 Category: Endocrinology Authors: Petrossians, P., Daly, A. F., Natchev, E., Maione, L., Blijdorp, K., Sahnoun-Fathallah, M., Auriemma, R., Diallo, A. M., Hulting, A.-L., Ferone, D., Hana, V., Filipponi, S., Sievers, C., Nogueira, C., Fajardo-Montanana, C., Carvalho, D., Hana, V., Stalla, Tags: Research Source Type: research

Cardiovascular outcomes and rates of fractures and falls among patients with brand-name versus generic L-thyroxine use
ConclusionsWe found no significant differences in cardiovascular outcomes and rates of falls and fractures for patients who filled brand versus generic L-thyroxine.
Source: Endocrine - June 5, 2021 Category: Endocrinology Source Type: research

New insights into the comorbid conditions of Turner syndrome: results from a long-term monocentric cohort study
ConclusionsThis cohort study confirms the need for continuous, structured and multidisciplinary lifelong monitoring of TS, thus ensuring the early diagnosis of important comorbid conditions, including cancer, and their appropriate and timely treatment. In addition, these data highlight the need for the increased surveillance of specific types of cancer in TS, including thyroid carcinoma.
Source: Journal of Endocrinological Investigation - July 30, 2022 Category: Endocrinology Source Type: research

Cardiovascular Outcomes of Differentiated Thyroid Cancer Patients on Long Term TSH Suppression: A Systematic Review and Meta-Analysis
Horm Metab Res 2023; 55: 379-387 DOI: 10.1055/a-2084-3408We performed a systematic review and meta-analysis of the literature regarding cardiovascular outcomes of differentiated thyroid cancer (DTC) patients who are on long term thyroid stimulating hormone suppression. Searches were carried out using Prisma guidelines in Medline, Embase, CENTRAL, CINAHL and Scopus databases. Eligible papers were those which investigated discrete cardiovascular clinical outcomes in TSH suppressed patients and meta-analysis of selected studies was performed using Revman 5.4.1. We found a total of 195 879 DTC ...
Source: Hormone and Metabolic Research - June 9, 2023 Category: Endocrinology Authors: Yu, Jerry Kaur, Rajneesh Ayeni, Femi Emmanuel Eslick, Guy D. Edirimanne, Senarath Tags: Original Article: Endocrine Care Source Type: research